华仁药业：全资子公司布美他尼原料药获上市批准

Core Viewpoint - Huaren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the listing of the raw material drug Bumetanide, which is indicated for severe heart failure, acute pulmonary edema, and adult hypertension, enhancing the company's product line and market competitiveness [1] Group 1 - The approval of Bumetanide will enrich the company's raw material drug product line [1] - The drug is effective for severe heart failure, acute pulmonary edema, and adult hypertension, showcasing its strong diuretic properties [1] - The approval is expected to boost the company's market sales and enhance its competitive edge [1] Group 2 - The development will support the synergistic growth of the company's raw material drugs, formulations, medical devices, and medical packaging sectors [1]